About Afraxis
Afraxis is a company based in San Diego (United States) founded in 2007. It operates as a B2B. Afraxis has raised $2 million across 5 funding rounds from investors including HHS. Afraxis operates in a competitive market with competitors including Cellply, Lucid Scientific, Kiyatec, CytoTronics and Saguaro, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Jurisdiction Bangalore North, Karnataka, India
-
Annual Revenue
$403.09 K (USD)19.31as on Mar 31, 2022
-
Net Profit
$26.11 K (USD)-14.87as on Mar 31, 2022
-
EBITDA
$31.2 K (USD)28.43as on Mar 31, 2022
-
Total Equity Funding
$2 M (USD)
in 5 rounds
-
Latest Funding Round
$204.51 K (USD), Grant
Sep 15, 2017
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Afraxis
Afraxis has successfully raised a total of $2M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $204.51 thousand completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Afraxis
Afraxis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Afraxis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Afraxis
Investment portfolio details for Afraxis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Afraxis
Detailed financials for Afraxis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Afraxis Comparisons
Peer comparison for Afraxis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Afraxis
Afraxis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cellply, Lucid Scientific, Kiyatec, CytoTronics and Saguaro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of in-vitro diagnostic products for the detection of cancer
|
|
| Locked | Locked | Locked |
Real-time cell analyzers are developed for oxygen consumption monitoring.
|
|
| Locked | Locked | Locked |
Kiyatec is focused on revolutionizing cancer care through predictive platforms.
|
|
| Locked | Locked | Locked |
Cell-based assays for drug discovery are developed via CMOS platform.
|
|
| Locked | Locked | Locked |
3D cell culture products are developed for drug discovery applications.
|
|
| Locked | Locked | Locked |
Metastatic cancer properties are targeted by Remedy Plan's containment therapy.
|
Detailed competitors of Afraxis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Afraxis
Complete news archive for Afraxis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Afraxis
Afraxis was founded in 2007 and raised its 1st funding round 2 years after it was founded.
Afraxis is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Afraxis is a funded company, having raised a total of $2M across 5 funding rounds to date.
Annual revenue of Afraxis is $403.09K as on Mar 31, 2022.
Afraxis, founded in 2007 in San Diego, United States, focuses on providing healthcare solutions, producing pharmaceutical products, drug screening, and cns technologies. Provides comprehensive CNS pharmaceutical screening technologies for pre-clinical evaluations. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
Afraxis's top competitors include CytoTronics, Kiyatec and Remedy Plan.
Afraxis has 1 investor. Key investors include HHS.